Steve M. Paul's most recent trade in Rapport Therapeutics Inc. was a trade of 21,850 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc. | Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 21,850 | 21,850 | - | - | Stock Option (Right to Buy) | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Other type of transaction at price $ 315.18 per share. | 29 Feb 2024 | 47,378 | 70,608 (0%) | 0% | 315.2 | 14,932,598 | Common Stock |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 30,304 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 2,364 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 32,668 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 10,000 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 30,304 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Feb 2024 | 30,304 | 40,304 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Paul M. Steven | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 27,510 | 757,045 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Steven M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.27 per share. | 23 Feb 2024 | 27,510 | 38,106 (0%) | 0% | 7.3 | 199,998 | Common Stock |
| Karuna Therapeutics Inc | Steven Paul M. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 99.72 per share. | 23 Feb 2024 | 4,008 | 42,114 (0%) | 0% | 99.7 | 399,678 | Common Stock |
| Karuna Therapeutics Inc | Paul M. Steven | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 4,008 | 135,992 | - | - | Option (right to buy) | |
| Karuna Therapeutics Inc | Paul Steven M. | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 317.14 per share. | 09 Feb 2024 | 804 | 10,596 (0%) | 0% | 317.1 | 254,981 | Common Stock |
| Sage Therapeutics Inc | M. Steve Paul | Director | 03 Jan 2024 | 3,971 | 3,971 | - | - | Stock Options (Right to buy) | ||
| Sage Therapeutics Inc | Steve M. Paul | Director | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| Karuna Therapeutics Inc | Steve M. Paul | Director, CSO and President of R&D | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2023 | 106,485 | 106,485 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steve M. Paul | Director, CSO and President of R&D | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2023 | 106,485 | 0 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steve M. Paul | Director, CSO and President of R&D | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2023 | 106,485 | 106,485 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steve M. Paul | Director, CSO and President of R&D | Gift of securities by or to the insider at price $ 0.00 per share. | 09 Feb 2023 | 106,485 | 0 (0%) | 0% | 0 | Common Stock | |
| Karuna Therapeutics Inc | Steve M. Paul | Director, CSO and President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 22,800 | 22,800 | - | - | Option (Right to Buy) | |
| Karuna Therapeutics Inc | Steve M. Paul | Director, CSO and President of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 11,400 | 11,400 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Steve M. Paul | Director | 04 Jan 2023 | 2,395 | 2,395 | - | - | Stock Options (Right to buy) | ||
| Sage Therapeutics Inc | Steve M. Paul | Director | 28 Nov 2022 | 5 | 78,539 (0%) | 0% | 38.2 | 191 | Common Stock | |
| Sage Therapeutics Inc | Steve M. Paul | Director | 16 Jun 2022 | 9,947 | 9,947 | - | - | Stock Option (Right to Buy) | ||
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.33 per share. | 01 Apr 2022 | 15,000 | 16,000 (0%) | 0% | 11.3 | 169,950 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2022 | 15,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 168.95 per share. | 01 Apr 2022 | 4,948 | 10,799 (0%) | 0% | 169.0 | 835,965 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 169.71 per share. | 01 Apr 2022 | 4,872 | 5,927 (0%) | 0% | 169.7 | 826,827 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 172.10 per share. | 01 Apr 2022 | 1,434 | 3,258 (0%) | 0% | 172.1 | 246,791 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 171.16 per share. | 01 Apr 2022 | 1,235 | 4,692 (0%) | 0% | 171.2 | 211,383 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 177.58 per share. | 01 Apr 2022 | 825 | 1,175 (0%) | 0% | 177.6 | 146,504 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 173.06 per share. | 01 Apr 2022 | 642 | 2,616 (0%) | 0% | 173.1 | 111,105 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 176.51 per share. | 01 Apr 2022 | 526 | 2,000 (0%) | 0% | 176.5 | 92,844 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 166.04 per share. | 01 Apr 2022 | 253 | 15,747 (0%) | 0% | 166.0 | 42,008 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 178.60 per share. | 01 Apr 2022 | 175 | 1,000 (0%) | 0% | 178.6 | 31,255 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steve M. Paul | Director | Sale of securities on an exchange or to another person at price $ 174.33 per share. | 01 Apr 2022 | 90 | 2,526 (0%) | 0% | 174.3 | 15,690 | Common Stock |
| Karuna Therapeutics Inc | Steve M. Paul | Director, President CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 146,900 | 146,900 | - | - | Option (right to buy) | |
| Sage Therapeutics Inc | Steve M. Paul | Director | 04 Jan 2022 | 1,638 | 1,638 | - | - | Stock Options (Right to buy) | ||
| Sage Therapeutics Inc | Steven M. Paul | Director | 09 Nov 2021 | 1 | 1 (0%) | 0% | 43 | 43 | Common Stock | |
| Karuna Therapeutics Inc | Steven M. Paul | Director, PRESIDENT CEO | Purchase of securities on an exchange or from another person at price $ 105.63 per share. | 17 Aug 2021 | 1,183 | 107,668 (0%) | 0% | 105.6 | 124,960 | Common Stock |
| Karuna Therapeutics Inc | Steven M. Paul | Director, PRESIDENT CEO | Purchase of securities on an exchange or from another person at price $ 106.10 per share. | 17 Aug 2021 | 1,181 | 108,849 (0%) | 0% | 106.1 | 125,304 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) | |
| Sage Therapeutics Inc | Steven M. Paul | Director | 10 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| Voyager Therapeutics Inc | Steven M. Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Karuna Therapeutics Inc | Steven M. Paul | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 161,850 | 161,850 | - | - | Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 18 Dec 2020 | 15,000 | 1,000 (0%) | 0% | 140 | 2,100,000 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.30 per share. | 18 Dec 2020 | 15,000 | 16,000 (0%) | 0% | 9.3 | 139,500 | Common Stock |
| Alnylam Pharmaceuticals Inc | Steven M. Paul | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 15,000 | 0 | - | - | Stock Option (right to buy) |